EMILY GEISE-SMITH: Open Payments
NPI 1538624978 · ELLICOTT CITY, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,023 in 41 payments from 13 companies in 2025. Trend: 2023 $900 · 2024 $859 · 2025 $1,023
Food & beverage: $1,023
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $246 |
| Madrigal Pharmaceuticals | 5 | $226 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $97 |
| Gilead Sciences, Inc. | 4 | $85 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $83 |
| Ardelyx, Inc. | 3 | $82 |
| Janssen Biotech, Inc. | 2 | $40 |
| PFIZER INC. | 2 | $35 |
| Regeneron Healthcare Solutions, Inc. | 1 | $30 |
| Celltrion USA Inc. | 1 | $28 |
Products named: REZDIFFRA, SKYRIZI, XIFAXAN, ENTYVIO, RINVOQ, IBSRELA, TREMFYA, VELSIPITY.
Industry payments across MD — which companies pay providers there.
